Log in to search using one of your social media accounts:

 

Chiasma and FDA agree on new Phase III trial design for acromegaly drug

The US Food and Drug Administration (FDA) has agreed on biopharmaceutical firm Chiasma ’s new Phase III clinical trial (OPTIMAL) design to evaluate its octreotide capsules product candidate Mycapssa as a maintenance therapy to treat adults with acrome…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Insulin resistance and the development of diabetes mellitus is a common complication of acromegaly. Prevalence of type 2 diabetes in acromegaly varies from 19 to 56% depending on the case series [1]. In acromegaly, high levels of growth hormone and subsequent stimulation of insulin-like growth factor 1 synthesis contribute to peripheral insulin resistance and the development of diabetes [2]. Although absolute insulin levels may be normal or high, the presence of severe insulin resistance may predispose to diabetic ketoacidosis.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
ConclusionThe risk-allele frequencies of studied polymorphisms in acromegaly were higher than in general European population. There is an association betweenFTO gene polymorphisms and HDL cholesterol concentration, suggestingFTO gene polymorphisms may be associated with higher CVD risk in patients with acromegaly.
Source: Pituitary - Category: Endocrinology Source Type: research
Key Clinical Message A 60‐year‐old man with a pre‐existing stable sacrococcygeal teratoma developed acromegaly, ectopic Cushing's syndrome, and 5HIAA secretion. To our knowledge, this represents the first reported case of ACTH and serotonin secretion, and likely GHRH or GH cosecretion, from a sacrococcygeal teratoma in an adult. A 60‐year‐old man with a pre‐existing stable sacrococcygeal teratoma developed acromegaly, ectopic Cushing's syndrome, and 5HIAA secretion. To our knowledge, this represents the first reported case of ACTH and serotonin secretion, and likely GHRH or GH cosecretion, from a sacrococcygea...
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: Case Report Source Type: research
Publication date: 5 December 2017 Source:Molecular and Cellular Endocrinology, Volume 457 Author(s): S. Cannavo, F. Trimarchi, F. Ferraù Increasing evidence suggests that environmental contaminants can exert endocrine disruptors activities and that pollution exposition can have a role in tumorigenic processes. Several environmental pollutants have been shown to affect pituitary cells biology and function. The aryl hydrocarbon receptor (AHR) pathway is involved in xenobiotics' metabolism and in tumorigenesis. A deregulation of the AHR pathway could have a role in pituitary tumours' pathophysiology, especially in the...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
Shivacharan Patel, Jigeeshu V Divatia, Sheila Nainan MyatraJournal of Anaesthesiology Clinical Pharmacology 2017 33(3):410-411
Source: Journal of Anaesthesiology Clinical Pharmacology - Category: Anesthesiology Authors: Source Type: research
CONCLUSIONS: In this article, we summarize the pathophysiology, clinical aspects and the new diagnostic tools to better understand bone impairment in acromegaly. PMID: 28880058 [PubMed - as supplied by publisher]
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
We present a 25‐year‐old man who presented with overgrowth of the right hand associated with occasional pain, numbness, and limited function who was found to have macrodystrophia lipomatosa with fibrolipomatous hamartoma of the median nerve. Reports of this condition are limited in the dermatology literature, and early recognition can lead to better outcomes.
Source: Pediatric Dermatology - Category: Dermatology Authors: Tags: Brief Report Source Type: research
ConclusionThe validation study underlined IGF-I and tumor status for routine clinical decision-making, whereas patient-oriented outcome measures received less medical attention. An Acromegaly Disease Activity Tool (ACRODAT) is in development that might assist clinicians towards a more holistic approach to patient management in acromegaly.
Source: Pituitary - Category: Endocrinology Source Type: research
CONCLUSION: The discriminant functions of detection developed in this study could help patients, their families, medical practitioners and others to identify and track progressive facial change patterns before the possible patients go to the hospital, especially the lateral "angles" which can be calculated by relative point-to-point changes derived from 2D lateral imagery without the 3D anthropometric measurements. This study tries to provide a novel and easy method to detect acromegaly when the patients start to have awareness of abnormal appearance because of facial measurement changes, and it also suggests tha...
Source: Neuroendocrinology Letters - Category: Endocrinology Tags: Neuro Endocrinol Lett Source Type: research
CONCLUSIONS: The psychiatric morbidity, mainly anxiety and insomnia, occurs in 50% of patients with acromegaly. However, the psychological wellbeing and mood seem to be related to other factor such as the acceptance of the illness. Thus, concerning the diagnosis, treatment and monitoring of acromegaly, an interdisciplinary approach, taking into account psychological and psychiatric consultation, is needed. PMID: 28879648 [PubMed - as supplied by publisher]
Source: Endokrynologia Polska - Category: Endocrinology Authors: Tags: Endokrynol Pol Source Type: research
More News: Acromegaly | Clinical Trials | Food and Drug Administration (FDA) | Pharmaceuticals